Skip to main content

Life Sciences is now live. See how →

Patent Examiner Charanjit Aulakh

Art Unit 1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions · Tech Center 1600 · 495 applications filed 2021–2026

⚑ Hard · harder than 64% of examiners● Free examiner data

Charanjit Aulakh is a USPTO patent examiner in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions) with 495 applications from filing years 2021–2026. Examiner Aulakh's allowance rate is 77.1%, below the 82.9% USPTO average for applications filed in the same years. The examiner ranks harder than 64% of examiners. In 2021, decided applications with an examiner interview were allowed 25.1 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 64% of examiners
Easier64th percentileHarder
Allowance rate vs peers
Examiner Aulakh77.1%
Art Unit 162169.3%
USPTO average82.9%
Allowance rate
77.1%
▼ USPTO avg 82.9%
Applications
495
filing years 2021–2026
First-action allowance
13.7%
patented with no rejection
Abandoned
17.6%
share of applications
Avg office actions
1.1
USPTO avg 1.3
Days to first OA
609
USPTO 617
RCE rate
12.1%
USPTO 19.3%
Interview rate
21.4%
USPTO 27.0%

Examiner details

  • Art unit1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions
  • Title / gradePrimary Patent Examiner · GS-14
  • Service30 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsAULAKH, CHARANJIT
Full signatory authority

Examiner Aulakh can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions546 · Organic Compounds (Class 532-570 Series)544 · Organic Compounds (Class 532-570 Series)

How to improve your odds with Examiner Aulakh

  • The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 14.7 to 28.5 points.
  • The timeline tracks the norm. First office action averages 609 days vs the 617-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (250), and applicants overcame it 71.1% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 4 measured years, by 1.7 to 32.6 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty103 issued · 68.7% overcome
§103 Obviousness75 issued · 71.0% overcome
§112 Definiteness & disclosure250 issued · 71.1% overcome
How applicants traverse §112 rejections🔒 Members

Of the 99 winning responses to Examiner Aulakh's §112 rejections that Boundly has classified, 73 (74%) amended the claims and argued, 22 amended without arguing, and 4 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Aulakh?

Draft your response with Examiner Aulakh's record and Art Unit 1621's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Aulakh.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
20248.2%100.0%82.8%+17.2pp
202310.0%85.7%84.0%+1.7pp
202214.4%100.0%67.4%+32.6pp
202115.0%83.3%70.3%+13.0pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/2629145-Fluoro-4-Imino-3-Methyl-1-Tosyl-3,4-Dihydropyrimidin-2(1H)-One for Controlling Plant DiseasesPatented1🔒 View
19/419278New Salt Forms of SabcomelinePatented2🔒 View
18/551214Treatment of Sickle Cell AnaemiaPatented2🔒 View
18/634083Tetradentate Platinum and Palladium Complexes Based on Biscarbazole and AnaloguesPatented5🔒 View
See all 495 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1621 technology

Pyrimidines & other diazinesPyridines & piperidinesKinase & enzyme inhibitorsMethods of treatmentTop CPC C07D · A61K · C07C
About this examiner. Charanjit Aulakh examines in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Charanjit Aulakh's allowance rate?
Examiner Aulakh's allowance rate is 77.1%, compared with 82.9% across the USPTO and 69.3% in Art Unit 1621 for applications filed in the same years. That rate ranks Examiner Aulakh harder than 64% of examiners.
Is Examiner Aulakh a hard examiner?
Somewhat. Examiner Aulakh ranks harder than 64% of examiners, in the 64th difficulty percentile (hard). Examiner Aulakh has a 77.1% allowance rate versus 82.9% across the USPTO and 69.3% in Art Unit 1621, 1.1 office actions per application versus 1.3, and an RCE rate of 12.1% versus 19.3% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Aulakh?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 4 measured years, by 14.7 to 28.5 percentage points. In 2021, 90.6% of decided applications with an interview were allowed, versus 65.5% of those without.
What is Examiner Aulakh's most common rejection?
§112 definiteness & disclosure, issued 250 times in the data. Applicants overcame it 71.1% of the time. Of the 99 winning responses Boundly has classified, 73 amended the claims and argued.
Is an RCE worth filing with Examiner Aulakh?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 4 measured years, by 1.7 to 32.6 percentage points. In 2021, 83.3% of decided applications with an RCE were allowed, versus 70.3% of those without one.
How long until the first office action from Examiner Aulakh?
About 609 days on average, versus 617 days across the USPTO for applications filed in the same years.
How do I contact Examiner Charanjit Aulakh?
Examiner Aulakh can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Aulakh's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Charanjit Aulakh, or see an error? Request a correction.